In the THINK study [128,129], NKG2D-targeted CAR T-cells were administered at doses of 3 × 108, 1 × 109 or 3 × 109 cells per infusion to patients with AML, MDS or multiple myeloma without lymphodepletion. Here, KLRK1 is linked to acute myeloid leukemia.